Percheron Therapeutics Limited ASX: PER Share Price & Review

PER Overview

PER Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About PER

Website

Percheron Therapeutics Limited

Telephone

61.3.9827.8999

Address

Level 30 35 Collins Street Collins Place Melbourne, Victoria (VIC) 3000

Description

Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.

PER Price Chart

Key Stats

Market Cap

AU$11.96M

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.14

Trade Value (12mth)

AU$28,128.00

1 week

10%

1 month

22.22%

YTD

37.5%

1 year

-86.9%

All time high

1.85

Key Fundamentals

EPS 3 yr Growth

-9.40%

EBITDA Margin

N/A

Operating Cashflow

-$10m

Free Cash Flow Return

-104.40%

ROIC

-123.00%

Interest Coverage

-4,107.90

Quick Ratio

2.80

Other Data

Shares on Issue (Fully Dilluted)

932m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PER Announcements

Latest Announcements

Date	Announcements
29 August 25	Percheron Receives $1.43m R&D Tax Incentive Rebate × Percheron Receives $1.43m R&D Tax Incentive Rebate
28 August 25	Appendix 4E and Annual Report × Appendix 4E and Annual Report
28 August 25	Appendix 4G and Corporate Governance Statement × Appendix 4G and Corporate Governance Statement
28 August 25	Notice of date of AGM and other relevant dates × Notice of date of AGM and other relevant dates
06 August 25	New Preclinical Data Reported for HMBD-002 in Breast Cancer × New Preclinical Data Reported for HMBD-002 in Breast Cancer
31 July 25	Quarterly Activities Report and Appendix 4C × Quarterly Activities Report and Appendix 4C
23 July 25	New Preclinical Data Reported for HMBD-002 × New Preclinical Data Reported for HMBD-002
01 July 25	Change of Director's Interest Notice - Dr James Garner × Change of Director's Interest Notice - Dr James Garner
30 June 25	Ceasing to be a substantial holder from PVL × Ceasing to be a substantial holder from PVL
27 June 25	Percheron Therapeutics Limited Corporate Presentation × Percheron Therapeutics Limited Corporate Presentation
26 June 25	Percheron licenses HMBD-002 from Hummingbird Bioscience × Percheron licenses HMBD-002 from Hummingbird Bioscience
25 June 25	Trading Halt × Trading Halt
20 May 25	Notification regarding unquoted securities - PER × Notification regarding unquoted securities - PER
20 May 25	Change of Directors Interest Notice - Dr Charmaine Gittleson × Change of Directors Interest Notice - Dr Charmaine Gittleson
20 May 25	Change of Director's Interest Notice - Dr James Garner × Change of Director's Interest Notice - Dr James Garner
14 May 25	Letter to eligible shareholders × Letter to eligible shareholders
14 May 25	Letter to ineligible shareholders × Letter to ineligible shareholders
07 May 25	Bonus Loyalty Option Offer × Bonus Loyalty Option Offer
07 May 25	Proposed issue of securities - PER × Proposed issue of securities - PER
30 April 25	Quarterly Activities Report and Appendix 4C × Quarterly Activities Report and Appendix 4C
24 April 25	Results of General Meeting × Results of General Meeting
22 April 25	Percheron Therapeutics General Meeting × Percheron Therapeutics General Meeting
22 April 25	Change of Interest of Substantial Holder from PVL × Change of Interest of Substantial Holder from PVL
03 April 25	Change of Director's Interest Notice - Dr Ben Gil Price × Change of Director's Interest Notice - Dr Ben Gil Price
02 April 25	Letter to Shareholders from the Board of Directors × Letter to Shareholders from the Board of Directors

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Falling Divs over next 2

Values and Recommendations

Key Stats

Consensus Score

Recommendation

EPS 1 month Change

Quality Yield

Falling Divs over next 2

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PER Shortsell

Frequently Asked Questions

What is the current share price of Percheron Therapeutics Limited (PER:ASX)?

The current share price of Percheron Therapeutics Limited (PER:ASX) is AU$0.011.

What is the 52-week high share price for Percheron Therapeutics Limited (PER:ASX)?

The 52-week high share price for Percheron Therapeutics Limited (PER:ASX) is AU$0.14.

What is the 52-week low share price for Percheron Therapeutics Limited (PER:ASX)?

The 52-week low share price for Percheron Therapeutics Limited (PER:ASX)? is AU$0.00.

What is the dividend yield for Percheron Therapeutics Limited (PER:ASX)?

Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.

What was Percheron Therapeutics Limited (PER:ASX) last dividend payment?

Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.

What is the franking level for Percheron Therapeutics Limited (PER:ASX)?

Percheron Therapeutics Limited (PER:ASX) has a franking level of 0.0%.

In which sector is Percheron Therapeutics Limited (PER:ASX) classified?

Percheron Therapeutics Limited (PER:ASX) is classified in the Healthcare.

The current P/E ratio for Percheron Therapeutics Limited (PER:ASX) is .